Novogene Future Growth

Future criteria checks 3/6

Novogene is forecast to grow earnings and revenue by 20.9% and 17.8% per annum respectively. EPS is expected to grow by 20.7% per annum. Return on equity is forecast to be 9.4% in 3 years.

Key information

20.9%

Earnings growth rate

20.7%

EPS growth rate

Life Sciences earnings growth	27.4%
Revenue growth rate	17.8%
Future return on equity	9.4%
Analyst coverage	Low
Last updated	12 May 2024

Recent future growth updates

Recent updates

Some Confidence Is Lacking In Novogene Co., Ltd. (SHSE:688315) As Shares Slide 26%

Jun 07

Time To Worry? Analysts Are Downgrading Their Novogene Co., Ltd. (SHSE:688315) Outlook

Apr 17

Estimating The Fair Value Of Novogene Co., Ltd. (SHSE:688315)

Mar 25

Earnings and Revenue Growth Forecasts

SHSE:688315 - Analysts future estimates and past financials data (CNY Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	3,245	308	N/A	431	3
12/31/2025	2,766	259	N/A	496	4
12/31/2024	2,332	212	N/A	276	4
6/30/2024	2,069	181	85	256	N/A
3/31/2024	2,030	183	97	251	N/A
12/31/2023	2,002	178	217	334	N/A
9/30/2023	1,990	190	171	280	N/A
6/30/2023	2,006	196	170	319	N/A
3/31/2023	1,980	181	278	465	N/A
12/31/2022	1,926	177	87	304	N/A
9/30/2022	1,955	209	180	398	N/A
6/30/2022	1,914	200	222	386	N/A
3/31/2022	1,888	211	122	247	N/A
12/31/2021	1,866	225	181	293	N/A
9/30/2021	1,812	218	235	340	N/A
6/30/2021	1,707	193	316	413	N/A
3/31/2021	1,633	132	406	518	N/A
12/31/2020	1,490	37	250	342	N/A
9/30/2020	1,437	-10	-98	18	N/A
6/30/2020	1,550	9	-196	-63	N/A
3/31/2020	1,472	37	-351	-214	N/A
12/31/2019	1,535	114	-87	85	N/A
9/30/2019	1,377	107	-57	101	N/A
6/30/2019	1,219	100	-26	117	N/A
3/31/2019	1,137	99	22	134	N/A
12/31/2018	1,054	97	70	151	N/A
12/31/2017	739	81	N/A	55	N/A
12/31/2016	458	39	N/A	95	N/A
12/31/2015	310	25	N/A	143	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 688315's forecast earnings growth (20.9% per year) is above the savings rate (2.9%).

Earnings vs Market: 688315's earnings (20.9% per year) are forecast to grow slower than the CN market (22% per year).

High Growth Earnings: 688315's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 688315's revenue (17.8% per year) is forecast to grow faster than the CN market (13.5% per year).

High Growth Revenue: 688315's revenue (17.8% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 688315's Return on Equity is forecast to be low in 3 years time (9.4%).

Novogene Future Growth

Future criteria checks 3/6

Key information

Recent future growth updates

Consensus EPS estimates fall by 13%

Price target decreased to CN¥28.89

Recent updates

Second quarter 2024 earnings released: EPS: CN¥0.12 (vs CN¥0.13 in 2Q 2023)

Novogene Co., Ltd. to Report First Half, 2024 Results on Aug 15, 2024

Some Confidence Is Lacking In Novogene Co., Ltd. (SHSE:688315) As Shares Slide 26%

Time To Worry? Analysts Are Downgrading Their Novogene Co., Ltd. (SHSE:688315) Outlook

First quarter 2024 earnings released: EPS: CN¥0.07 (vs CN¥0.06 in 1Q 2023)

Now 21% undervalued after recent price drop

Novogene Co., Ltd., Annual General Meeting, May 06, 2024

Novogene Co., Ltd. to Report Q1, 2024 Results on Apr 13, 2024

Estimating The Fair Value Of Novogene Co., Ltd. (SHSE:688315)

Full year 2023 earnings: EPS and revenues miss analyst expectations

Novogene Co., Ltd. (SHSE:688315) announces an Equity Buyback for CNY 160 million worth of its shares.

Investor sentiment deteriorates as stock falls 17%

Now 20% overvalued

New minor risk - Share price stability

New minor risk - Shareholder dilution

New minor risk - Share price stability

Third quarter 2023 earnings released: EPS: CN¥0.12 (vs CN¥0.14 in 3Q 2022)

Investor sentiment deteriorates as stock falls 16%

Consensus EPS estimates fall by 13%

Novogene Co., Ltd. to Report First Half, 2023 Results on Aug 01, 2023

First quarter 2023 earnings released: EPS: CN¥0.06 (vs CN¥0.07 in 1Q 2022)

Full year 2022 earnings released: EPS: CN¥0.44 (vs CN¥0.58 in FY 2021)

Novogene Announces Deployment of Illumina NovaSeq™ X Plus and PacBio REVIO Sequencing Systems

Investor sentiment improved over the past week

Price target decreased to CN¥28.89

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: CN¥0.14 (vs CN¥0.12 in 3Q 2021)

Investor sentiment deteriorated over the past week

Novogene America Unveils Superpowered Robot Scientist for Autonomously Intelligent NGS Delivery- Falcon II

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.087 (vs CN¥0.13 in 2Q 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Full year 2021 earnings: EPS and revenues miss analyst expectations

Full year 2021 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorated over the past week

Now 25% undervalued after recent price drop

Third quarter 2021 earnings released: EPS CN¥0.12 (vs CN¥0.07 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.13 (vs CN¥0.037 loss in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.09 (vs CN¥0.17 loss in 1Q 2020)

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies